Halda is inventing novel precision medicines for oncology.  Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer.  This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today’s precision cancer medicines.  Using a novel ‘hold and kill’ mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. 

We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. 

We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. 

Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.


Biotechnology

Halda Therapeutics

Halda Therapeutics' headquarters in New Haven, CT, United States

Craig Crews

Scott Phillips

Eyal Attar

The Research and Development team at Halda Therapeutics is dedicated to the discovery and advancement of innovative RIPTAC™ therapeutics for oncology. Comprising skilled scientists and researchers, the team conducts cutting-edge experiments to understand the mechanisms of cancer and to develop targeted treatments that effectively overcome drug resistance. Their collaborative efforts focus on advancing the company's pipeline of precision medicines, ultimately aiming to provide novel solutions for patients suffering from drug-resistant cancers.

Research and Development

The Research and Development team at Halda Therapeutics plays a pivotal role in advancing the company's innovative RIPTAC™ therapeutics for oncology. This collaborative team, comprised of experts in biology and chemistry, focuses on designing and optimizing novel chemical compounds, conducting in-depth biological profiling, and ensuring rigorous testing to evaluate the efficacy of new drug candidates. By leveraging their scientific expertise and state-of-the-art lab facilities, the team aims to push the boundaries of drug discovery and address the urgent needs of cancer patients facing drug resistance.

The Leadership Team at Halda Therapeutics, comprising the Chief Scientific Officer, Founder, and Chief Financial Officer, is responsible for setting the strategic direction of the company and overseeing its innovative drug development initiatives. They collaborate closely to ensure that the RIPTAC™ therapeutics pipeline aligns with Halda’s mission to address unmet needs in oncology, while also managing financial resources and fostering a culture of creativity and teamwork within the organization. Their collective expertise drives the advancement of novel precision medicines and enhances Halda’s position as a leader in tackling drug-resistant cancers.

Halda Therapeutics

Org chart

Teams

Research and Development

Research and Development

Leadership Team

Offices

Halda Therapeutics

Org chart

Teams

Research and Development

Research and Development

Leadership Team

Offices

Related companies